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AbstrAct
Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease (CVD), such that the risk 
of cardiovascular mortality is greater than the risk of progression to end-stage kidney disease. Despite the increased 
prevalence of traditional and non-traditional cardiovascular risk factors, patients with kidney disease have been 
mostly under-represented in previous cardiovascular outcome studies, thereby resulting in a paucity of data on the 
evidence-based management of CVD in CKD. In this review, we explore the evidence on the burden of CVD and 
its risk factors in patients with CKD, highlight various inflammatory biomarkers for predicting CVD and provide an 
overview on novel biomarkers for CVD.
Keywords: chronic kidney disease; cardiovascular disease; cardiovascular disease risk factors.
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INtrODUctION
Ever since the link between chronic kidney disease (CKD) 
and cardiovascular disease (CVD) was established about 
two decades ago, several epidemiological studies have 
confirmed and even extended this finding. Patients with 
CKD are more likely to develop CVD than their age-
matched counterparts in the general population, so 
much so that the risk of death from CVD is much higher 
than the risk of eventually requiring dialysis [1]. Sarnak 
et al. [2] showed that CKD is a strong predictor of CVD 
and suggested that it should be recognized as a coronary 
disease risk equivalent, like diabetes mellitus. Declining 
renal function represents a continuum of cardiovascular 
risk and in those individuals who reach end-stage kidney 
disease (ESKD) the risk of suffering a cardiac event is 
extremely high [3].
Even though increased frequencies of traditional and 
non-traditional risk factors have been well documented 
in CKD patients, those with kidney disease have been 
mostly under-represented in previous cardiovascular 
outcome studies, thereby resulting in a paucity of data 
on the evidence-based management of CVD in CKD. In 
this review we explore the evidence on the burden of 
CVD and its risk factors in CKD patients, highlight various 
inflammatory biomarkers for predicting CVD and provide 
an overview on novel biomarkers for CVD. 
OVErVIEW OF cVD IN cKD
The various forms of CVD that may affect patients with 
CKD are listed in Table 1. A study that evaluated the 
pattern of cardiac lesions among haemodialysis patients 
in Cameroon found high frequencies of cardiac lesions 
including left ventricular hypertrophy (60%), valvular cal-
cifications (38%), cardiac failure (36%) and conduction 
abnormalities (33%) [4]. These findings probably repre-
sent the tip of the iceberg because CVD was defined on 
the basis of electrocardiographic and echocardiographic 
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abnormalities; subclinical lesions such as increased carotid 
intimal media thickness (CIMT) and atherosclerotic plaques 
were not captured. Among black CKD patients receiving 
care in a tertiary health facility in South Africa, we reported 
a higher prevalence of carotid atherosclerotic vascular 
disease (AsVD) in stage 3 CKD and ESKD patients compared 
to controls. AsVD was more prevalent among peritoneal 
dialysis (PD) patients compared to haemodialysis (HD) and 
CKD stage 3 patients [5]. In a previous study, we also 
reported an increased prevalence of left ventricular hyper-
trophy (LVH) among kidney transplant recipients compared 
to controls [6]. Heart failure, a common CVD in CKD 
patients, may present as acute left ventricular failure or 
congestive cardiac failure (CCF). It may present as diastolic 
dysfunction, less often as systolic dysfunction, or as a 
combination of both. A study that evaluated elderly CKD 
patients found that the relative risk of developing heart 
failure was 1.45 and 1.68 in CKD stages 1–2 and 3–5, 
respectively [7]. The prevalence of peripheral arterial 
disease (PAD) is high in patients with CKD and inversely 
related to kidney function [8]. Sudden cardiac death (SCD) 
is an entity with complex pathophysiological mechanisms 
including structural and electrophysiological remodelling in 
the heart, CKD-related inflammation, sympathetic activa-
tion, myocardial ischaemia, metabolic acidosis, altered nitric 
oxide levels and dialysis-related factors such as electrolyte 
shifts across cell membranes and hypotension. According 
to the United States Renal Data System (USRDS), one-
quarter of all-cause mortality among dialysis patients was 
attributed to cardiac arrest [9]. 
EPIDEMIOLOGY OF cVD IN cKD
In a previous study, we evaluated the prevalence of AsVD 
and its predictors among Black patients with stage 3 CKD 
or ESKD on continuous ambulatory peritoneal dialysis 
(CAPD) or HD. AsVD was most prevalent among CAPD 
patients, occurring in 70%, compared to 47.5% among HD 
patients and 17.1% among controls [5]. Similarly, Go et al. 
[10] reported an association between lower GFR and 
CVD. The adjusted hazard ratio increased from 1.4 in CKD 
stage 3 to 3.4 in patients with ESKD. Liu et al. [11] reported 
an association between CAD and CKD among patients 
who underwent coronary angiography; 18.8% of patients 
with CAD had CKD compared with 5.4% without CAD. 
The term cardiorenal syndrome (CRS) is increasingly being 
used to define a pathophysiological condition in which 
cardiac and renal dysfunction coexist. A single-centre retro-
spective cohort study of 1,087 patients admitted to an 
internal medicine ward in Italy had a CRS prevalence of 
17.5% [12].
rIsK FActOrs FOr cVD IN cKD
In 1961, the Framingham Heart Study group introduced 
the concept of CVD risk factors by linking the presence of 
previously identified clinical conditions to the development 
of future CVD [13]. The risk factors in patients with CKD 
are categorised as traditional or non-traditional (Table 2). 
Risk factors for cardiovascular disease in CKD
table 1.  Spectrum of cardiovascular diseases in chronic 
kidney disease.
A.  Peripheral and cerebrovascular disease
Arterial hypertension
Atherosclerosis causing limb ischaemia
Stroke
B.  Myocardial disease
Myocardial ischaemia and infarction
Left ventricular hypertrophy
Cardiomyopathy
Myocarditis
C.  Pericardial disease
Uraemic pericarditis
D.  Others
Arrhythmias
Cardiac autonomic dysfunction
Sudden cardiac death
table 2.  Risk factors for cardiovascular disease in CKD.
Traditional Non-traditional
Hypertension             Inflammation
Diabetes mellitus       Endotoxaemia
Smoking    Oxidative stress
Older age                                                Hyperhomocysteinaemia
Males Anaemia
Obesity Abnormal calcium–phosphate metabolism
Higher LDL cholesterol    
Lipoprotein (a) and apolipoprotein (a) 
isoforms
Lower HDL cholesterol   Advanced glycation end products (AGES)
Family history of CVD Asymmetric dimethylarginine (ADMA)
Menopause  Malnutrition
Physical inactivity  Proteinuria
LVH    Extracellular fluid volume overload 
Renin angiotensin system overactivity
Endothelial dysfunction
Pro-thrombotic state
Elevated fibroblast growth factor 23  
(FGF-23) levels
Abbreviations: LDL, low density lipoprotein; HDL, high density lipoprotein;  
CVD, cardiovascular disease; LVH, left ventricular hypertrophy.
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Certain traditional risk factors may be aggravated by CKD. 
Patients with CKD also have additional risk factors such 
as inflammation, oxidative stress, endothelial dysfunction, 
anaemia, and calcium–phosphate abnormalities that are 
related to the uraemic milieu.
trADItIONAL rIsK FActOrs
Hypertension
Hypertension is a risk factor for mortality in CKD patients. 
The blood pressure–mortality association is J-shaped, 
suggesting an ideal blood pressure that is neither too high 
nor too low. Isolated raised systolic blood pressure (and 
wide pulse pressure) appears to increase long-term mor-
tality risk and low BP (mean and diastolic) predicts early 
mortality [14]. The Action to Control Cardiovascular Risk 
in Diabetes BP trial (ACCORD BP), which evaluated 4,733 
hypertensive diabetic patients, showed that lowering BP to 
below the standard target of 140 mmHg reduced the risk 
of stroke by about 40% [15]. 
Diabetes mellitus
Diabetes mellitus is a cardiovascular risk equivalent and 
diabetic patients are at increased risk of cardiovascular 
mortality, with a 2-fold risk of death from cardiovascular 
causes compared to those without diabetes [16]. 
cigarette smoking
Smoking increases the risk of CVD in kidney disease 
patients and may accelerate the progression of kidney 
disease. Evidence has demonstrated the beneficial effects 
of stopping smoking among cohorts of male smokers 
followed up for 50 years [17]. Current smokers had a 
2-fold increased risk of CKD compared to former smokers, 
and the number of cigarettes smoked daily predicted the 
likelihood of having CKD. Guidelines have recommended 
stopping or complete avoidance of smoking as an integral 
part of a CKD management strategy.  
Age 
The association of blood pressure variation with ageing was 
clearly demonstrated in the Framingham study, and age has 
been shown to be an important predictor of cardiovascular 
events. A cross-sectional study of CVD risk factors among 
Black Africans with CKD found a positive correlation 
between CIMT and age [18].
Obesity
Increased waist–hip ratio was shown to be associated with 
fatal cardiovascular events among stages 3 and 4 CKD 
patients pooled from the Atherosclerosis Risk in Com-
munities (ARIC) study and Cardiovascular Health Study 
[19]. This study concluded that the cardiovascular risk 
related to obesity may be underestimated by body mass 
index [19].
Dyslipidaemia
Dyslipidaemia is one of the traditional CVD risk factors that 
is worsened by CKD. Elevated triglyceride levels may be 
due to delayed catabolism of triglycerides from down-
regulation of the gene for lipoprotein lipase or an increase 
in lipoprotein lipase inhibitor [20]. Furthermore, the dialysis 
modality used in ESKD could have procedure-dependent 
effects on serum levels of triglyceride, although this remains 
a subject of controversy. In addition to increasing hepatic 
lipoprotein output, massive proteinuria increases gene 
expression for the enzymes hydroxyl-3-methylglutaryl- 
CoA reductase (HMG-CoA reductase) and cholesterol 
7a-hydroxylase, which are rate-limiting steps in cholesterol 
biosynthesis and catabolism to bile acids [21]. This strength-
ens the need for early commencement of anti-proteinuric 
therapy with angiotensin-converting enzyme inhibitors 
(ACE-I) or angiotensin receptor blockers (ARB). Reduction 
of LDL-C with statin therapy has been shown to signifi-
cantly reduce CVD in CKD patients [22]. The JUPITER 
study showed that rosuvastatin prevented major 
atherosclerotic events in apparently healthy men and 
women, thus justifying subsequent evaluation of the effect 
of statins on CVD in high-risk groups such as CKD patients. 
Similarly, among kidney transplant recipients, a randomised 
controlled trial, Assessment of Lescol in Kidney Trans-
plantation (ALERT), showed that fluvastatin reduced 
cardiac death and non-fatal myocardial infarction (relative 
risk 0.65) compared to placebo [23]. Furthermore, a 
landmark multicentre trial, the Study of Heart and Renal 
Protection (SHARP), recruited over 9,000 CKD patients 
and evaluated the cardiovascular effect of lowering LDL-C 
with a combination of simvastatin and ezetimibe compared 
to placebo [22]. The study demonstrated a reduction of 
17% in the first major atherosclerotic event including non-
fatal myocardial infarction or coronary death, non-haem-
orrhagic stroke or arterial revascularisation in the treat-
ment group [22]. 
sex
Males are more predisposed to cardiovascular disease. In a 
South African study with 7,188 participants, the prevalence 
of ischaemic heart disease was higher among males (18.4% 
vs 13.1%) [24]. 
Physical activity
There is consistent evidence suggesting an association 
between physical activity and reduced CVD morbidity and 
mortality, with reports from several population studies 
showing that there is a 2-fold rise in the risk of CAD in 
individuals with a sedentary lifestyle compared to those 
Risk factors for cardiovascular disease in CKD
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who were active [25]. The risk associated with sedentary 
lifestyle is comparable to that conferred by hypertension, 
cigarette smoking or hypercholesterolaemia. 
Left ventricular hypertrophy
Levin et al. [26] showed that the prevalence of LVH 
increases with advancing renal failure; LVH was present in 
26.7% of patients with GFR greater than 50 mL/min, 30.8% 
of patients with GFR between 25 and 49 mL/min, and 
45.2% of patients with GFR of <25 mL/min. Left ventricular 
mass index (LVMI) was inversely associated with GFR; 
LVMI in CKD patients with GFR >50 mL/min, 25–50 mL/
min and <25 mL/min were 97.5 g/m2, 100.8 g/m2 and 114.4 
g/m2, respectively. Uraemia causes remodelling of the 
heart muscle, leading to LVH, fibrosis and left ventricular 
dysfunction [27]. 
NON-trADItIONAL rIsK FActOrs
Declining GFr
Reduced GFR is closely related to the presence of 
cardiovascular disease. In a study that assessed the pre-
dictors of CAD among 800 patients with CKD, significantly 
lower eGFR was found among participants who had CAD 
compared to those without [28]. 
Proteinuria
Meta-analysis of cohorts with cardiovascular events showed 
a graded increase in the risk of CAD with elevated 
proteinuria [29]. Moderately elevated albuminuria was 
associated with a 50% increase in the risk of CAD (HR = 
1.47), whereas the risk is doubled in patients with macro-
albuminuria (HR = 2.17). Schmieder et al. [30] showed that 
elevations in proteinuria predicted mortality among patients 
with vascular disease but normal GFR. 
Anaemia
Anaemia is associated with LVH, is present in approximately 
75% of patients initiating dialysis and is a major predictor of 
cardiovascular morbidity and mortality [26]. In dialysis 
patients, every 1 g/dL reduction in haemoglobin was asso-
ciated with left ventricular dilatation (OR 1.46), heart failure 
and mortality [31]. Although the role of hypoxia inducible 
factors (HIF) in erythropoietin production have been 
described in CKD, there are no data on the relationship 
between HIF and atherosclerosis.
calcium–phosphate abnormalities and 
secondary hyperparathyroidism
Alterations in the serum levels of calcium, phosphate, 
vitamin D and parathyroid hormone (PTH) are frequently 
encountered in CKD. A robust association has been estab-
lished between hyperphosphataemia and LVH and cause-
specific mortality in patients on haemodialysis [32, 33]. 
Hyperphosphataemia is associated with increased coronary 
artery calcification in haemodialysis patients. Apart from the 
contribution of calcium–phosphate abnormalities to vas-
cular calcification, alterations in the levels of the physiological 
regulators of vascular calcification such as fetuin-A, osteo-
protegerin and matrix-GLA protein, significantly influence 
vascular calcification in CKD patients. Among HD patients, 
plasma levels of osteoprotegerin predicted all-cause (RR 
2.67) and cardiovascular (RR 3.15) mortality [34].
chronic inflammation and  
inflammatory biomarkers
The aetiology of chronic inflammation in ESKD patients is 
multifactorial, arising from immune dysregulation and 
inflammatory activation, including decreased renal clearance 
and increased production of cytokines, intestinal dysbiosis 
with increased translocation of gut bacteria into the 
systemic circulation, periodontal disease, increased pro-
inflammatory and oxidative stress from uraemic toxins, 
metabolic acidosis, vitamin D deficiency-associated immune 
dysfunction and dialysis-related factors [35]. The relationship 
between elevated C-reactive protein (CRP) and CVD in 
ESKD patients was documented among maintenance HD 
patients in South Africa [36]. The available evidence sug-
gests a link between chronic inflammation and accelerated 
atherosclerosis. In support of this finding, we demonstrated 
that circulating endotoxaemia was common among South 
African CKD patients, and was associated with left ven-
tricular mass index [37]. In another study, we showed that 
endotoxaemia was associated with a 4-fold increased risk 
of atherosclerosis [38]. Taken together, this evidence sug-
gests that chronic inflammation may be a mediator of 
accelerated atherosclerosis in CKD patients.
Oxidative stress
Oxidized LDL, a marker of oxidative stress, has been 
shown to play a crucial role in the pathogenesis of CAD, 
hypertension and atherosclerosis [39]. Oxidative stress 
depletes endogenous nitric oxide, resulting in endothelial 
dysfunction, which triggers the process of left ventricular 
remodelling and fibrosis, and oxidation of lipoproteins. 
Endothelial dysfunction
Nitric oxide is produced by endothelial NO synthase 
(eNOS), which has vasodilator, antiplatelet, anti-prolifera-
tive, anti-adhesive, permeability-decreasing and anti-inflam-
matory properties. Impaired function or non-availability of 
NO will induce immune activation and systemic inflam-
Risk factors for cardiovascular disease in CKD
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mation, ultimately leading to atherosclerosis and CAD. 
Asymmetric dimethylarginine (ADMA), a naturally occurring 
inhibitor of NOS, has been shown to accumulate and 
contribute to the CVD burden in CKD patients [40].
Hyperhomocysteinaemia
Lower levels of homocysteine are associated with reduced 
risk of cardiovascular events, and a meta-analysis of studies 
that investigated the association between the methylenete-
trahydrofolate reductase gene (MTHFR) and risk of 
coronary heart disease further suggested that this asso-
ciation is causally related [41].  
Adiponectin
Adiponectin is a major risk factor for type 2 diabetes, 
obesity, insulin resistance, metabolic syndrome, visceral 
adiposity, and atherosclerosis [36]. In addition, a negative 
correlation has been established between eGFR and 
adiponectin levels [36]. Even though it is thought that 
excretion of adiponectin in ESKD patients may be impaired, 
it remains to be seen whether elevated levels of adiponectin 
in CKD patients are due to impaired clearance or a com-
pensatory mechanism militating against increased cardio-
vascular risks in CKD patients.
Fibroblast growth factor 23
Fibroblast growth factor 23 (FGF-23) plays a key role in 
calcium–phosphate metabolism and is directly related to 
kidney function. In CKD patients, FGF-23 is a predictor of 
myocardial hypertrophy, and pharmacological reduction of 
FGF-23 through blockage of the FGF-23 receptor resulted 
in improvement of LVH, further suggesting that FGF-23 
antagonists may be a potential therapeutic strategy to 
reduce CVD in CKD [42].
Genetic susceptibility to  
cardiovascular disease
Many genetic polymorphisms have been examined for their 
role in modifying CVD risk in CKD patients. Polymorphisms 
in the Apolipoprotein L1 (APOL1), interleukin-6 (IL-6), 
fibroblast growth factor (FGF-23) and hypoxia-inducible 
factor (HIF) genes, to mention but a few, have been 
associated with increased risk for CVD in CKD. The Jackson 
Heart Study (JHS) and Women’s Health Initiative (WHI) 
study evaluated asso-ciations between APOL1 high-risk 
genotypes and renal and cardiovascular diseases. They 
showed that the APOL1 G1/G2 variants, that decrease 
autophagosome functions, removal of pro-atherosclerotic 
cells and clearance of oxidized LDL, significantly increased 
the burden of atheroscle-rotic CVD in African Americans 
(JHS and WHI combined, odds ratio, 2.12), suggesting a 
genetic component to CVD disease in CKD patients of 
African ancestry [43]. In support of this finding, we recently 
showed that Black South African CKD patients who are 
carriers of at least one APOL1 risk allele had a 3-fold 
increased risk of subclinical atherosclerosis (odds ratio 
3.19), and the presence of high-risk APOL1 risk variants 
was strongly associated with increased oxidized LDL 
levels [44]. Furthermore, the association between maternal 
APOL1 genetic variants and pre-eclampsia, an important 
risk factor for hypertension, CKD and CVD, was explored 
in pregnant women of African ancestry. These same high-
risk APOL1 variants were associated with early-onset pre-
eclampsia [45].   
Inflammation plays a crucial role in atherosclerosis and 
other manifestations of CAD. Genetic polymorphism 
(−174G/C) on the IL-6 gene is associated with atheroscle-
rotic CVD in dialysis patients [46]. Corroborating this 
finding, we recently reported an association between IL-6 
gene polymorphism and IL-6 levels as well as atheroscle-
rosis among Black South African CKD patients [47]. 
FGF-23 has been identified as an independent cardiovas-
cular risk marker in multiple patient populations. Schwantes-
An et al. [48] reported an association between poly-
morphisms in the FGF-23 gene and cardiovascular (CV) 
mortality and heart failure in haemodialysis patients. FGF-
23 rs11063112 was associated with a 32% and 37% 
increased risk of CV mortality and heart failure, respectively, 
in patients of European ancestry, and 31% and 51% among 
patients of African ancestry. 
The chromosomal region 14q23.2 contains the gene for 
the alpha subunit of the transcription factor HIF-1, a key 
factor in the adaptation to ischaemia/hypoxia. Genetic 
variants are associated with acute myocardial infarction and 
intradialytic hypotension in haemodialysis patients [49].
Genome-wide association studies have yielded strong 
evidence that the 9p21.3 locus is associated with CAD in 
diverse populations. Akan et al. [50] demonstrated asso-
ciations between 9p21.3 polymorphisms and CAD risk 
among Tanzanian patients; the GG genotypes (rs10757274 
and rs10757278) were associated with a 3-fold and 4-fold 
increased risk of CAD, respectively. It remains to be seen 
how CKD will impact on the association between 
chromosome 9p21 variants and CAD risk factors in African 
populations.
cONcLUsIONs
The burden of CVD in CKD patients is huge and 
multifactorial in nature, with contributions from traditional 
as well as non-traditional risk factors. Cardiac and vascular 
insults stem from ventricular remodelling, endothelial 
dysfunction, uraemia, anaemia, inflammation and vascular 
Risk factors for cardiovascular disease in CKD
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calcifications. Ethnically diverse patterns of cardiovascular 
disease suggest that, at least in part, there are genetic 
factors which influence these complications in patients 
with CKD.
The huge morbidity and mortality associated with coexisting 
CKD and CVD highlights the importance of early identi-
fication and treatment of cardiovascular risk factors in at-
risk individuals. The public-health implications of early 
detection of CVD are enormous, particularly in sub-Saharan 
Africa where resources for health are inadequate. Improved 
governmental support for the early detection and treatment 
of patients with CKD is imperative. This must include 
prompt identification of CVD risk factors and appropriate 
therapeutic interventions.
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